Recombinant humanized monoclonal Anti-TrkA antibody

重组人源化抗TrkA单克隆抗体

Report date: 2023/07/25 16:59:48

Base Information

Drug NameRecombinant humanized monoclonal Anti-TrkA antibody
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionNerve growth factor receptor Trk-A antagonists
TargetsNerve growth factor receptor Trk-A
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesXiyuan Anjian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXiyuan Anjian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A